Please use this identifier to cite or link to this item:
Title: Incorporating Biomarker Stratification into STAMPEDE: An Adaptive Multi-arm, Multi-stage Trial Platform
Authors: Gilson, C.;Chowdhury, S.;Parmar, M. K.B.;Sydes, M. R.
subject: Biomarkers;Clinical trial design;Platform trials;Precision medicine;Prostate cancer
Year: 2017
Abstract: The treatment and outcomes for advanced prostate cancer have experienced significant progress over recent years. Importantly, the additional benefits of 'up front' chemotherapy (docetaxel) and abiraterone, over and above conventional androgen deprivation, have been separately demonstrated in the multi-arm, multi-stage (MAMS) STAMPEDE protocol, which continues recruitment to other questions. Alongside this, insights into the underlying molecular biology and, inevitably, the molecular heterogeneity of prostate cancer are opening the door to new therapeutic approaches. Incorporating this understanding and testing these hypotheses within STAMPEDE brings new challenges to the MAMS approach, but has the potential to further improve the outlook for this disease.
ISSN: 4420767049
volume: Volume 29
issue: Issue 12
month: December
Appears in Collections:clinical oncology 2017

Files in This Item:
File Description SizeFormat 
2017 CONCOLOGY Volume 29 Issue 12 December (10).pdf431.57 kBAdobe PDFThumbnail
Download    Request a copy

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.